Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020.

Nader, Jaclynne H; Bourgeois, Florence; Bagatell, Rochelle; Moreno, Lucas; Pearson, Andrew D J; DuBois, Steven G

Nader, Jaclynne H; Bourgeois, Florence; Bagatell, Rochelle; Moreno, Lucas; Pearson, Andrew D J; DuBois, Steven G.

Affiliation

Nader JH; UMass Chan Medical School, Worcester, Massachusetts, USA.
Bourgeois F; Harvard Medical School, Boston, Massachusetts, USA.
Bagatell R; Pediatric Therapeutics and Regulatory Science Initiative, Computational Health Informatics Program (CHIP), Boston Children's Hospital, Boston, Massachusetts, USA.
Moreno L; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Pearson ADJ; Paediatric Oncology and Haematology Division, Vall d'Hebron Hospital, Barcelona, Spain.
DuBois SG; Division of Clinical Studies, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.

Pediatr Blood Cancer ; 70(5): e30106, 2023 05.

Article in En | MEDLINE | ID: mdl-36458672

Subject(s)

Antineoplastic Agents; Neuroblastoma; Humans; Neuroblastoma/drug therapy; Antineoplastic Agents/therapeutic use; Combined Modality Therapy; Drug Development

Key words

EMA; FDA; combination; monotherapy; neuroblastoma; novel; oncology; pediatric

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neuroblastoma / Antineoplastic Agents Type of study: Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2023 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google